Liver Cancer

Severe Fatigue is an Important Factor in the Prognosis of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib

Publish Date September 18, 2020

[Cancer Management and Research] Researchers present a simple classification method for assessing fatigue, which is proven to be a prognostic marker of TTP and OS in patients with HCC.

FDA Denies Accelerated Approval of Keytruda Plus Lenvima for Unresectable HCC

By

Brian Park, PharmD

Publish Date July 14, 2020

In the CRL, the FDA stated that the data from KEYNOTE-524/Study 116 did not demonstrate a meaningful advantage over available therapies for unresectable or metastatic HCC.

Drug-Related Hypertension Associated with the Efficacy of Apatinib on Hepatocellular Carcinoma

Publish Date June 26, 2020

[Cancer Management and Research] Researchers sought to determine if apatinib-related hypertension was a predictor of drug efficacy in patients with advanced HCC.

Immunotherapy Regimen Approved for Hepatocellular Carcinoma

By

Brian Park, PharmD

Publish Date June 5, 2020

The FDA has approved Tecentriq® in combination with Avastin® for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.

Survival Benefit Seen With Atezolizumab-Bevacizumab Combo in Unresectable HCC

By

Leah Lawrence

Publish Date May 25, 2020

The combination resulted in durable response in many patients.

Liver Cancer Clinical Trials

NSCLC: Study Assesses Adjuvant Chemo Decision-making Role Preferences

Clinical Trial: Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer

Clinical Trials: Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery

Clinical Trial: Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer

Clinical Trial: Fusion Guided Thermal Ablation Combined With External Beam Radiation for Hepatic Neoplasms.